Food and drug administration (fda) and clarivate extend material transfer agreement for three additional years

Partnership enables agency-wide access to off-x translational safety intelligence solution london , may 23, 2023 /prnewswire/ -- clarivate plc (nyse: clvt), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the extension of the material transfer agreement (mta) with the fda for an additional three years. the extension will ensure continued agency-wide access to off-x™ by clarivate, which provides integrated preclinical toxicity, clinical and post-marketing adverse event data, visualizations and analytics.
CLVT Ratings Summary
CLVT Quant Ranking